Major R&D Pipeline: 3ADCs
DS-5670 (COVID-19 mRNA vaccine)
Characteristics of DS-5670
Lipid nanoparticle (LNP)-mRNA
DS original cationic lipid is applied
Most optimized lipid and lipid composition ratio are selected
based on efficacy & safety perspectives
It is expected to be effective against variants as well by
targeting Receptor Binding Domain (RBD) instead of
full spike protein of SARS-Cov-2
Participating in "Fundamental Research on the Control of a Novel Corona Virus (2019-nCoV)",
an initiative supported by the Japan Agency for Medical Research and Development (AMED).
Initiated Ph1/2 study in March 2021 and completed subject enrollment. Currently evaluating
the safety, immunogenicity and recommended dose.
Planning to initiate active-controlled, non-inferiority confirmatory study this year,
enrolling several thousand subjects. Submission for approval and commercialization within
CY2022 in the case when all regulatory requirements are satisfied.
Daiichi-Sankyo
22View entire presentation